Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

Posts Tagged ‘blood’

Inaugurazione Kennedy Yanko Because it’s in my blood

Posted by fidest press agency su martedì, 28 luglio 2020

Milano 4.09 – 20.11.2020 Inaugurazione giovedì 24.09.2020 dalle 18:30 alle 21:00Galleria Poggiali, Foro Buonaparte 52. Dopo le importanti mostre degli ultimi anni negli USA, fra le altre quella al Museum of Contemporary Art di Detroit e quella alla galleria Kavi Gupta di Chicago, Kennedy Yanko lo scorso anno ha realizzato 3 WAYS, la sua prima opera pubblica presso il Poydras Corridor a New Orleans in collaborazione con The Helis Foundation e l’Ogden Museum of Art. Nello stesso anno è stata nominata per l’Art Forum’s “Critic’s Pick” e ha ricevuto il Colene Brown Art Prize dalla BRIC Arts Media. In questi stessi giorni Yanko inaugurera la sua personale, SALIENT QUEEN, presso la galleria VIELMETTER di Los Angeles.
Because it’s in my blood, è un omaggio a Betty Davis. Il titolo è preso in prestito dalla canzone F.U.N.K contenuta nell’album Nasty Gal del 1975. Simbolo di una generazione ed esempio di emancipazione sia per le donne che per la comunità afroamericana, Betty Davis, attraverso la sua musica, ha espresso la volontà di non dare per scontate le regole imposte da una società basata su principi ingiusti, gridando la sua indipendenza e rigettando tutte le regole alle quali, al tempo, e forse ancora oggi, la nostra società si aspetta che una donna afroamericana si attenga. Ora ritorna più attuale che mai la necessità di essere liberi, di esprimere sé stessi senza censure. Censurare qualcosa solo perché non si è in grado di comprenderlo significa privarsi, sia individualmente che collettivamente, di crescita, turbamento e messa in discussione.In mostra nella galleria Milanese, sette nuove produzioni, frutto di una ricerca che l’artista porta avanti dal 2017; opere di dimensioni variabili, dalle più piccole, Jimmie e Space alla più grande Crow, sono tutte realizzate in bronzo e pelle dipinta. Si tratta di uno studio nato da una prima serie di lavori, Elements and Skin (2017), nella quale frammenti di metallo recuperato erano uniti a pelle di vernice policroma. Negli ultimi anni Kennedy Yanko ha continuato a lavorare su queste stesse coordinate attraverso un processo di sottrazione e semplificazione. Ispirata dai dipinti ad olio realizzati su supporti in rame tipicamente rinascimentali e dall’uso del colore monocromo tipico delle avanguardie del secolo scorso, l’artista ha sviluppato un corpus di lavori realizzati in rame di riuso e pelle verniciata a tinte monocroma. Le opere nascono da un processo mentale, l’impiego materiali di recupero, che portano con sé il proprio vissuto, consente nel loro riutilizzo, una nuova vita.Per Kennedy Yanko è fondamentale porre lo spettatore davanti al non ovvio e farlo ragionare su come noi tutti abbiamo un’idea predefinita di qualsiasi cosa. Davanti ad un’opera d’arte pensiamo di aver già capito tutto, mentre in realtà abbiamo solamente grattato la sua superficie. Il metallo fa pensare subito all’industria, alla tecnologia ma per quest’artista non c’è niente di più lontano: il rame ad esempio, è un’entità vivente, con una sua anima e una sua storia, ognuno dei suoi lavori ha un suo portato e una sua sensibilità.Le opere esposte in Because it’s in my blood si sottraggono alle aspettative, alle associazioni e alle nozioni preconcette nello spirito di Betty Davis, dei surrealisti e di coloro che lottano continuamente per annullare la fissità delle concezioni umane. I lavori contengono uno spirito sovversivo, invitano lo spettatore a esaminarli e riesaminarli, richiedono del tempo. A prima vista, il rame affilato sostiene l’installazione e la pelle fragile, scivola via. Dall’altro, la pelle si arrampica all’interno delle cavità di rame. Le dinamiche relazionali sono aperte e indefinite, in continua evoluzione. Un’irrisolvibile ambiguità.In occasione della mostra verrà realizzato un volume edito dalla Galleria Poggiali contenete un testo critico dello scrittore e curatore newyorchese Cristian Viveros-Fauné. Viveros-Fauné collabora con importanti testate internazionali, di settore e non, come ad esempio Art in America, artnet, Artnews, ArtNexus, Frieze, The New Yorker e The New York Press; si ricordano inoltre alcuni dei suoi testi critici scritti per mostre di grande successo, fra cui, Authentic/Ex-centric: Conceptualism in Contemporary African Art (49° Biennale di Venezia), Beuys and Beyond (Deutsche Bank Collection traveling exhibition), Ahmed Alsoudani (Phoenix Art Museum, Phoenix, USA).

Posted in Cronaca/News, Mostre - Spettacoli/Exhibitions – Theatre | Contrassegnato da tag: , | Leave a Comment »

Aβ Blood Test for Detecting Early Alzheimer’s Disease Pathology

Posted by fidest press agency su sabato, 14 dicembre 2019

C2N Diagnostics today announced that results from a study of the APTUS™-Aβ blood test showed high performance for identifying presence or absence of Alzheimer’s pathology in the brain. The APTUS™-Aβ blood test measures amyloid beta proteins from a single sample of blood. The study showed that this blood test reliably predicts the presence or absence of brain amyloid, an essential and early marker of Alzheimer’s disease. Dr. Tim West, Vice President of Research & Development for C2N Diagnostics reported the results as part of a Late Breaking Session at the 12th Annual CTAD conference, held Friday, December 6, 2019 in San Diego, CA.In the study, C2N applied the APTUS™-Aβ blood test to 415 samples previously collected from individuals enrolled at six different locations across the United States. Despite differences in how each of the sites previously collected and stored the blood samples, as well as how each site defined presence of amyloid in the brain, the results showed that the APTUS™-Aβ blood test yielded an area under the receiver operator curve (ROC-AUC) performance of 0.86. When the APTUS™-Aβ results were combined with age and presence of the ApoE4 gene, a known genetic risk factor for developing Alzheimer’s disease, the overall test performance increased to an AUC of 0.90.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Development of a New Blood Test That May Predict Responders to Checkpoint Inhibitor Therapies

Posted by fidest press agency su domenica, 27 ottobre 2019

Calviri, Inc., a start-up focused on ending deaths from cancer through unconventional approaches to diagnostics and vaccines, was recently awarded a $300,000 Phase I grant through the Small Business Innovation Research Program (SBIR) at the National Cancer Institute (NCI). This one-year grant will support the development of a new test for establishing whether a cancer patient’s tumor has high microsatellite instability (MSI-H). This is important because MSI-H status is associated with very favorable responses to checkpoint inhibitor immunotherapies.
Calviri’s research is centered on the discovery of a new source of neoantigens produced by tumor cells. Instead of point mutations in DNA, Calviri focuses on frameshift (FS) variants produced through errors in RNA processing, such as mis-splicing. Calviri has demonstrated that these frameshifted peptides are a rich source of highly immunogenic neoantigens. Since there are a limited number of possible FS peptides, they can be predicted and produced in-situ on arrays manufactured by the company’s proprietary process. Studies indicate that MSI-H patients produce many more immune responses specific to the FS peptides than microsatellite stable (MSS) patients. The product in development will identify and quantify those FS neopeptides that are made by a patient’s tumor and recognized by their blood-antibodies. Currently MSI status is determined by sequencing defined genes of tumor cells. This depends on obtaining sufficient tumor tissue for DNA sequencing protocols. Under this SBIR grant, Calviri will determine whether the FS peptide arrays can readout microsatellite instability status from a drop of blood. The study will be conducted with blood samples from colon and endometrial cancer patients to assess if the same FS array can determine MSI status for more than one cancer. Calviri expects to report study results in early 2020.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders

Posted by fidest press agency su giovedì, 3 ottobre 2019

Basel Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older. GPA and MPA are rare, potentially life-threatening diseases affecting small and medium sized blood vessels.
The approval is based on data from the PePRS study, a Phase IIa, global, open-label, multicentre single-arm study investigating the safety, pharmacokinetics, exploratory efficacy and pharmacodynamic outcomes of intravenous MabThera/Rituxan in 25 patients with active GPA or MPA between 6 and 17 years of age. Treatment with four weekly infusions of MabThera/Rituxan in combination with a tapering course of oral glucocorticoids was assessed in newly diagnosed or relapsing active GPA or MPA paediatric patients. Of the 25 patients in the study, 19 had GPA and 6 had MPA at baseline. Efficacy was an exploratory endpoint and primarily assessed using the Paediatric Vasculitis Activity Score (PVAS). Efficacy assessment showed that 56% of patients achieved PVAS remission by month 6, 92% by month 12, and 100% of patients achieved remission by month 18. The safety profile of MabThera/Rituxan in patients with paediatric GPA and MPA was consistent in type, nature and severity with the known safety profile of MabThera/Rituxan in adult patients with GPA and MPA, rheumatoid arthritis and pemphigus vulgaris.The FDA previously granted Priority Review to Rituxan for the treatment of GPA and MPA in paediatric patients. In 2011, Rituxan became the first and only therapy approved by the FDA for the treatment of adults with these two rare forms of vasculitis. MabThera/Rituxan is currently indicated for the treatment of four autoimmune conditions and since 2006 more than 900,000 people have been treated with MabThera/Rituxan for autoimmune conditions worldwide. MabThera/Rituxan is not indicated in children less than 2 years of age with GPA or MPA, or in children with conditions outside of GPA and MPA.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Biotech Company Detraxi Is Developing a Solution to Eliminate Global Blood Shortages

Posted by fidest press agency su martedì, 23 luglio 2019

The demand for blood in China exceeds supply, with blood products only satisfying 50% of the total demand. According to The World Health Organisation, 0.92% of China’s population are donating blood, which falls below the rate of 1% to 3% that is needed to meet demand. The annual clinical blood demand growth rate is 10-15%.Blood collection doubled between 2011 and 2016 to 7000 tons. In 2018, 18.4 million units of blood were allocated across China. 15.8 million units were allocated locally within the same Province as collection. But managing blood supplies is hugely complex. Refrigerated blood only remains viable for between 35 and 42 days.Biotechnology is currently undergoing exponential technological progression and improving by a factor of 10 every year in terms cost-benefit. This is driving new biotech solutions that have not been available before. The global biotech market is expected to reach US$741.7 billion by 2026. Synthetic biotech is expected to exceed more than US$12.5 billion by 2024 with a CAGR of 20%, according to MarketWatch.
However, the development of new biotechnologies requires a very high appetite for risk and lots of patience. Detraxi is backed by London and Hong Kong-based technology billionaire Tej Kohli. Kohli believes that biotechnologies such as Detraxi will offer solutions to some of the world’s greatest public health challenges.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Second-Generation Blood Test for Irritable Bowel Syndrome (IBS)

Posted by fidest press agency su giovedì, 23 Maggio 2019

Gemelli Biotech, in partnership with the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, announced new findings that validate a second-generation diagnostic blood test for irritable bowel syndrome (IBS) as the most accurate ever. Available commercially as ibs-smart™, the test could provide physicians with the most conclusive data currently attainable for ruling in IBS. Primarily applicable to patients with a diarrheal component to their symptoms, the test could serve up to two-thirds of the 45 million Americans suffering from IBS.After over a decade of uncovering the pathophysiology of post-infectious IBS, researchers at Cedars-Sinai validated the antibodies anti-CdtB and anti-vinculin as highly specific biomarkers measurable in blood. This innovative blood test offered patients the first-ever opportunity to receive a diagnosis of IBS by ruling in the disease, rather than by ruling out other diseases.Scientists at the Medically Associated Science and Technology program at Cedars-Sinai, in collaboration with Gemelli Biotech, developed a proprietary epitope optimization process that was instrumental to improving the test for its second-generation launch as ibs-smart™. Cedars-Sinai has entered into an exclusive license agreement with Gemelli Biotech for several patent applications covering the blood test technology.At Digestive Disease Week (DDW 2019) in San Diego, the MAST team reported the results of their validation study. The second-generation blood test is >90% specific in distinguishing patients with IBS from patients with Inflammatory Bowel Disease using each marker. When combined, the post-test probability of IBS is >98%. That means that for the first time, a near certain diagnosis of IBS can be made if both biomarkers are elevated.
Gemelli Biotech is determined to bring ibs-smart™ to physicians worldwide. Physicians in the US can order the test for patients via a kit-based system. The company helps interested patients find local specialists and blood draw labs. Samples are tested in a CLIA-certified lab in Irvine, California. The test is covered at least in part by most insurance providers.
Dr. Mark Pimentel, Executive Director of the MAST program, as well as a practicing gastroenterologist and co-founder of Gemelli Biotech, believes the greater diagnostic accuracy is meaningful to patients and doctors alike. “As a physician, I want to know what is causing the disease in my patient, and I want to know as efficiently as possible. This test tells me that my patient has IBS and I can get to the desired therapy without undue testing.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Blood of King Albert I of Belgium identified after 80 years

Posted by fidest press agency su domenica, 24 luglio 2016

King Albert IThe death of King Albert I of Belgium in 1934 – officially a climbing accident – still fuels speculation. Forensic geneticist Maarten Larmuseau and his colleagues at KU Leuven (University of Leuven, Belgium) have now compared DNA from blood found on the scene in 1934 to that of two distant relatives. Their analysis confirms that the blood really is that of Albert I. This conclusion is at odds with several conspiracy theories about the king’s death.
On 17 February 1934, King Albert I – the third King of the Belgians – died after a fall from the rocks in Marche-les-Dames, in the Ardennes region of Belgium near Namur. Albert I was popular and world famous due to his role during the First World War. The fact that there were no witnesses to his death soon fuelled speculations about the king’s ‘real’ cause of death.
Conspiracy theories are circulating to this very day, ranging from a political murder to a crime of passion: the king is said to have been murdered elsewhere, his dead body has allegedly never been in Marche-les-Dames, or his fall is believed to have been staged only later. Evidence for these theories, however, has never been found.
After the death of Albert I, Marche-les-Dames virtually became a place of pilgrimage, and relics turned up with the king’s trails of blood, said to have been collected during the night of 17 to 18 February by people living in the neighbourhood.
VTM journalist Reinout Goddyn, who works for the Flemish television programme Royalty, bought one of these relics: blood-stained tree leaves. He wanted to know if this could really be the blood of Albert I, given the conspiracy theories. In 2014, UGent Professor Dieter Deforce had already confirmed that the blood was definitely human.
Forensic geneticist Maarten Larmuseau and his colleagues from KU Leuven (University of Leuven, Belgium) continued the investigation and found two living relatives of Albert I:
“King Simeon II of Saxe-Coburg and Gotha, the last tsar and former prime minister of Bulgaria who is related to Albert I on his father’s side, and Anna Maria Freifrau von Haxthausen, a German baroness who is related to Albert I on her mother’s side, were willing to cooperate. They gave up DNA samples, which we compared with the DNA of the trails of blood. We found that the blood is indeed that of Albert I.”
This confirmation has historical importance. “80 years after the fact, everyone involved has passed away, and most material is gone; we will probably never be able to dismiss all speculations concerning this ‘cold case’. This study was one of the last possibilities to gather additional data. The authenticity of the trails of blood confirms the official account of the death of Albert I. The story that the dead body of the king has never been in Marche-les-Dames or was only placed there at night has now become very improbable. Furthermore, the results show that conducting a perfect legal investigation at the time was impossible right from the start, because souvenir hunters had disturbed the scene.” This type of genetic family-tree research confronts researchers with quite a few ethical questions, adds bioethicist Pascal Borry from the KU Leuven Interfaculty Centre for Biomedical Ethics and Law: “We have to take into account the consequences of this study for living relatives. After all, in addition to the actual identification, a genetic profile can reveal quite a bit of sensitive information, in the context of a kinship analysis or in terms of hereditary conditions. This particular case concerns someone who’s deceased and has obviously never given permission for a genetic profile.”
“We only focused on the identification of the trails of blood and deliberately avoided deducing unexpected results from the DNA,” Larmuseau continues. “The latter was the most difficult aspect of this study. We also want to protect the privacy of everyone involved and of living relatives, and avoid commercialization of the genetic information, following international guidelines for biomedical research. Therefore, the genetic profiles have not been published, but they were double-checked by independent experts. The DNA samples of our study have been destroyed. What is left of the relic will be entrusted to an institution for cultural heritage or to a scientific institution.” (photo: King Albert I)

Posted in Estero/world news, Spazio aperto/open space | Contrassegnato da tag: , , | Leave a Comment »